Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Baxter
Argus Health
Fuji
Johnson and Johnson
US Army
Covington
Cipla
Farmers Insurance
Federal Trade Commission

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,227,471

« Back to Dashboard

Which drugs does patent 8,227,471 protect, and when does it expire?

Patent 8,227,471 protects ADDYI and is included in one NDA.

This patent has thirty-nine patent family members in twenty-nine countries.
Summary for Patent: 8,227,471
Title:Treating sexual desire disorders with flibanserin
Abstract: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
Inventor(s): Borsini; Franco (Bad Waldsee, DE), Evans; Kenneth Robert (Toronto, CA)
Assignee: Sprout Pharmaceuticals, Inc. (Raleigh, NC)
Application Number:11/524,268
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,227,471

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,227,471

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01125020Oct 20, 2001

Non-Orange Book US Patents Family Members for Patent 8,227,471

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,151,103 Method of treating female hypoactive sexual desire disorder with flibanserin ➤ Subscribe
9,468,639 Treating sexual desire disorders with flibanserin ➤ Subscribe
9,782,403 Treating sexual desire disorders with flibanserin ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,227,471

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 78974 ➤ Subscribe
Slovenia 1446122 ➤ Subscribe
Serbia 50876 ➤ Subscribe
Yugoslavia 30004 ➤ Subscribe
Portugal 1446122 ➤ Subscribe
Poland 208744 ➤ Subscribe
Poland 367358 ➤ Subscribe
New Zealand 532079 ➤ Subscribe
Norway 325556 ➤ Subscribe
Norway 20041588 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
QuintilesIMS
Novartis
Farmers Insurance
Johnson and Johnson
Dow
Argus Health
Teva
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot